BioNTech
Mainz, Germany · Biopharma, Biotechnology, Health Care
BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases.
Key facts
- Headquarters
- Mainz, Germany
- Employees
- 5,000
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (BNTX)
- Website
- www.biontech.com
- Company page
Recent activity at BioNTech
- : BioNTech Appoints Guido Oelkers as Chief Executive Officer
- : University of Pennsylvania and BioNTech establish a $50m partnership to fund early-stage life sciences ventures.
- : BioNTech completes acquisition of CureVac
- : BioNTech and Bristol Myers Squibb Form Strategic Partnership to Develop BNT327 for Solid Tumor Treatment
- : BioNTech and Bristol Myers Squibb Form $11B Partnership for Cancer Drug Development.
- : BioNTech Appoints Ramón Zapata as Chief Financial Officer
- : BioNTech completes acquisition of Biotheus to strengthen oncology strategy
- : BioNTech Acquires Biotheus, Gains Control of Investigational Bispecific Antibody
- : BioNTech Appoints Annemarie Hanekamp as Chief Commercial Officer
- : BioNTech SE
BioNTech funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Venture | $150.0M |
| Sep 2020 | Venture | $250.0M |
Leadership
- Helmut Jeggle, Director
- Michael Motschmann, Director
- Christoph Huber, Director
- Ulrich Wandschneider, Director
- Luca Dezzani, Vice President US Medical Affairs
- Guido Oelkars, Chief Executive Officer
- Guido Oelkers, Chief Executive Officer
Verified email and direct lines for BioNTech’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
BioNTech files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BioNTech in the news
- Despite Trial Misses, BioNTech Keeps Focused on mRNA Cancer Therapies - GenomeWeb (Nov 03, 2026)
- BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases - Fierce Biotech (Oct 26, 2026)
- European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union - BioNTech (Jul 29, 2026)
- BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning - Yahoo Finance (Oct 28, 2026)
- BioNTech Q3 2026 Earnings Call Transcript - Benzinga (Nov 03, 2026)
- BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update - The Manila Times (Nov 03, 2026)
- How the Pfizer-BioNTech Vaccine Works (Published 2022) - The New York Times (Dec 05, 2020)
- Pfizer-BioNTech shot for children under 5 safe and effective, FDA staff says - The Washington Post (Jun 12, 2022)
Companies similar to BioNTech
- Jazz Pharmaceuticals plc · Biopharma, Biotechnology, Health Care, Therapeutics
- Alnylam Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Foresee Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
- Daiichi Sankyo · Biopharma, Biotechnology, Health Care, Therapeutics
- BIAL · Biopharma, Biotechnology, Health Care, Therapeutics
About BioNTech: questions and answers
What does BioNTech do?
BioNTech is a biopharmaceutical company dedicated to harnessing the power of the immune system to develop innovative cancer therapies and treatments for other serious diseases.
Where is BioNTech headquartered?
BioNTech is headquartered in Mainz, Germany.
How many employees does BioNTech have?
BioNTech has about 5,000 employees.
Has BioNTech raised funding?
Yes. Fundz has recorded 2 funding events for BioNTech. The most recent, $150.0M, was in Apr 2022.
Who leads BioNTech?
Luca Dezzani is a Vice President US Medical Affairs at BioNTech.
What is the latest news on BioNTech?
On Aug 03, 2026, BioNTech Appoints Guido Oelkers as Chief Executive Officer
Is BioNTech a public company?
Yes. BioNTech is publicly traded under the ticker BNTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy